Ken Griffin Ac Immune Sa Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$2.99 - $4.2 $112,125 - $157,500	-37,500 Reduced 99.73%	100 $0
Q2 2024 Aug 14, 2024	BUY	$2.29 - $4.87 $12,595 - $26,785	5,500 Added 17.13%	37,600 $150,000
Q1 2024 May 15, 2024	BUY	$2.66 - $4.87 $73,416 - $134,412	27,600 Added 613.33%	32,100 $95,000
Q4 2023 Feb 14, 2024	BUY	$2.46 - $5.0 $10,824 - $22,000	4,400 Added 4400.0%	4,500 $22,000
Q3 2023 Nov 14, 2023	SELL	$2.77 - $3.38 $5,540 - $6,760	-2,000 Reduced 95.24%	100 $0
Q2 2023 Aug 14, 2023	BUY	$1.85 - $3.4 $2,590 - $4,760	1,400 Added 200.0%	2,100 $6,000
Q1 2023 May 15, 2023	SELL	$2.13 - $2.49 $12,354 - $14,442	-5,800 Reduced 89.23%	700 $1,000
Q4 2022 Feb 14, 2023	BUY	$1.72 - $3.12 $11,180 - $20,280	6,500 New	6,500 $13,000

28.2M

150K

12.4K

Ticker ACIU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,413,504
Market Cap $296M
Description
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectiv...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.